---

---

publishing date : 2022 - 12 - 15    tags : Research   

save search

---

Ocean Power Technologies to Participate in a Fireside Chat with Water Tower Research on Friday, December 16
Published: 2022-12-15 (Crawled : 23:00) - globenewswire.com
OPTT | $0.185 -2.27% -2.16% 300K |

Producer Manufacturing

| -67.27% | O: -3.0% H: 3.09% C: 3.09%
water research

---

TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments
Published: 2022-12-15 (Crawled : 21:00) - biospace.com/
MTAC 4 | $11.34 18.67% 180K |

| -7.39% | O: 2.73% H: 0.0% C: -3.09%
sciences research pre-clinical life trial

---

Negative Pressure Wound Therapy Market Size to Reach USD 4.27 Billion in 2030| Emergen Research
Published: 2022-12-15 (Crawled : 18:00) - prnewswire.com
STMH | $0.1 -88.3% 2.2K |

Manufacturing

| 506.06% | O: 0.0% H: 21.21% C: 21.21%
CAH | $103.54 0.16% -0.52% 2.1M |

Distribution Services

| 31.81% | O: -0.64% H: 0.97% C: 0.67%
MMM | $92.02 -1.05% 0.0% 3.8M |

Producer Manufacturing

| -27.02% | O: -1.03% H: 0.23% C: -1.93%
SMTI 4 | $32.74 0.43% 0.43% 5.3K |

Health Services

| -9.92% | O: -1.61% H: 6.87% C: 4.34%
research therapy negative market

---

Global Rare Disease Drugs Market Report 2022-2027: Increasing Focus on Research Activities and Development of Novel Therapeutic Drugs to Facilitate Future Growth
Published: 2022-12-15 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -0.48% | O: -0.85% H: 0.0% C: 0.0%
TAK | News | $13.23 -1.12% 0.0% 920K |

Health Technology

| -14.15% | O: -0.71% H: 0.07% C: -1.05%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 6.29% | O: -0.71% H: 0.08% C: -1.07%
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 1.78% | O: -0.59% H: 0.44% C: -0.48%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -0.33% | O: 0.04% H: 0.0% C: 0.0%
rare research global disease report growth market

---

Interactive Display Market Size to Reach USD 18.81 Billion in 2030| Emergen Research
Published: 2022-12-15 (Crawled : 17:00) - prnewswire.com
NIPNF | $72.0 -52.94% 490 |

Technology Services

| Email alert Add to watchlist
research market

---

Chili's celebrates $100 million raised to benefit St. Jude Children's Research Hospital
Published: 2022-12-15 (Crawled : 15:20) - prnewswire.com
EAT | $47.59 -0.85% -1.24% 770K |

Consumer Services

| 33.38% | O: -1.85% H: 1.17% C: 0.11%
research

---

FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder
Published: 2022-12-15 (Crawled : 14:20) - biospace.com/
EHVVF | $0.001 155.0% 34K |

Professional, Scientific, and T...

| -83.05% | O: 13.56% H: 11.94% C: 4.48%
fda ketamine grants study major depressive disorder

---

Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT
Published: 2022-12-15 (Crawled : 14:20) - biospace.com/
RLYB | News | $1.59 -8.62% -9.43% 280K |

| -74.96% | O: 9.83% H: 10.53% C: 1.3%
publication

---

Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease
Published: 2022-12-15 (Crawled : 14:20) - biospace.com/
SEEL | $0.2971 -9.17% -10.1% 600K |

Health Technology

| -76.74% | O: 3.1% H: 0.0% C: -18.05%
sls-004 disease parkinson's therapeutics therapy study

---

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
ALPMY | News | $9.49 -1.11% 480K |

Manufacturing

| -41.0% | O: -2.18% H: 0.0% C: -0.83%
fx-345 candidate therapeutics study phase 2b

---

Vivos Therapeutics Announces New Revenue Stream Through Strategic Medical Billing Relationship with Nexus Dental SystemsNew Collaboration to Increase Payer Reimbursements and Patient Access
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
VVOS | $2.58 -2.64% -2.71% 75K |

Health Technology

| 642.77% | O: 0.0% H: 4.88% C: 0.72%
collaboration medical therapeutics

---

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular EdemaRZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
RZLT 4 | $2.91 1.75% 1.72% 340K |

Technology Services

| 90.13% | O: 0.66% H: 2.61% C: -2.61%
rz402 macular eye alternative potential therapy study diabetic

---

BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
BCRX | News | $4.22 -3.65% -3.79% 4.4M |

Health Technology

| -62.31% | O: -6.0% H: 8.76% C: 2.95%
bcx9930 potential

---

Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
TLSA | News | $0.781 0.77% 0.77% 330K |

Health Technology

| 41.05% | O: 1.95% H: 0.7% C: 0.7%
sciences pre-clinical life study

---

Immunocore is awarded the Prix Galien France award for KIMMTRAK
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
IMCR | $58.52 2.11% 2.07% 390K |

Manufacturing

| -0.83% | O: -1.17% H: 4.5% C: 1.97%
award kimmtrak

---

Zentek Announces Successful Phase 2 Results of HVAC Testing
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
ZTEK | $1.14 1.33% 13K |

Professional, Scientific, and T...

| -34.1% | O: 2.89% H: 0.0% C: -6.74%
IKTSY | $62.1945 -12.21% 2.4K |

Professional, Scientific, and T...

| 21.09% | O: -1.86% H: 0.0% C: -0.96%
results phase 2

---

AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
Published: 2022-12-15 (Crawled : 12:20) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M |

Health Technology

| 13.85% | O: -1.17% H: 0.48% C: -0.55%
lynparza treatment review update cancer prostate cancer

---

Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
Published: 2022-12-15 (Crawled : 12:20) - biospace.com/
ATXS | $9.02 -6.43% -6.87% 660K |

Manufacturing

| -18.26% | O: 8.99% H: 10.83% C: -6.17%
star-0215 trial therapeutics positive results

---

Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine
Published: 2022-12-15 (Crawled : 12:20) - biospace.com/
RVPH | $3.02 -1.31% -1.32% 78K |

| -25.25% | O: 2.48% H: 11.35% C: -0.72%
pharmaceuticals brilaroxazine positive study

---

IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL
Published: 2022-12-15 (Crawled : 12:20) - biospace.com/
IMV | $0.8225 -2.74% 45K |

Health Technology

| -61.02% | O: 30.33% H: 0.0% C: 0.0%
ongoing trial phase 2b

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---